Platform has the potential to identify combination therapies against a specific cancer
Imagine a person with cancer, who is able to have a tumor biopsied and receive a treatment plan ideally suited to that particular type of cancer, all within a day or two. Jonathan Dordick is working on this very research.
“This whole platform really gives us a way to optimize personalized immunotherapy on a rapid, high throughput scale.”
— Jonathan Dordick, Institute Professor of Chemical and Biological Engineering
A testing platform more closely mimicking what cancer encounters in the body may allow for more precise, personalized therapies by enabling the rapid study of multiple therapeutic combinations against tumor cells. Furthering the potential use of this tool requires testing on a wide range of cancer types. In the future, he envisions enabling the identification and delivery of personalized immunotherapy.